A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease.

about

Mucocutaneous IL-17 immunity in mice and humans: host defense vs. excessive inflammation.Increased serum IL-17 and decreased serum IL-10 and IL-35 levels correlate with the progression of COPD

P2860

Q49551961-57DD7AB2-D840-4C13-BD6C-A3AF557A5E6F Q58735852-5F645A66-BE43-4F5D-BE28-49F49680D692

P2860

A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease.

Item

http://www.wikidata.org/entity/Q38373177

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

A Randomized, Placebo-Controll ...... Obstructive Pulmonary Disease.

@en

type

Item

label

A Randomized, Placebo-Controll ...... Obstructive Pulmonary Disease.

@en

prefLabel

A Randomized, Placebo-Controll ...... Obstructive Pulmonary Disease.

@en

P1476

A Randomized, Placebo-Controll ...... Obstructive Pulmonary Disease.

@en

P2093

Andreas Eich

http://www.w3.org/2001/XMLSchema#string

Chong-Kin Liam

http://www.w3.org/2001/XMLSchema#string

Christopher D O'Brien

http://www.w3.org/2001/XMLSchema#string

Jae Jeong Shim

http://www.w3.org/2001/XMLSchema#string

Jiri Vlcek

http://www.w3.org/2001/XMLSchema#string

Jun Xiao

http://www.w3.org/2001/XMLSchema#string

Patrick Branigan

http://www.w3.org/2001/XMLSchema#string

Ping-Hung Kuo

http://www.w3.org/2001/XMLSchema#string

Vasiliy I Trofimov

http://www.w3.org/2001/XMLSchema#string

Veronika Urban

http://www.w3.org/2001/XMLSchema#string

P2860

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

CD8 positive T cells express IL-17 in patients with chronic obstructive pulmonary disease.

Anti-interleukin-17 antibodies attenuate airway inflammation in tobacco-smoke-exposed mice.

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma.

One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.

Long-acting muscarinic receptor antagonists for the treatment of respiratory disease.

The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.

Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.

T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients.

P304

1-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/15412555.2017.1335697

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Marek Jutel

P577

2017-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28753067

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease

placebo

phase II clinical trial

A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease.

about

P2860

P2860

A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P50

P577

P698

P921